Detail of "280744-09-4"

Reference

Glycogen synthase kinase-3 inhibitors protect central neurons against excitotoxicity

Glycogen synthase kinase-3 inhibitors protect central neurons against excitotoxicity.Several substances are used for example 280744-09-4 and 56-86-0 which are their cas registry numbers. Facci, Laura; Stevens, David A.; Skaper, Stephen D. (Neurophysiology and Cell Sciences, Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research and Development Ltd., Essex CM19 5AW, UK). NeuroReport, 14(11), 1467-1470 (English) 2003 Lippincott Williams & Wilkins. CODEN: NERPEZ. ISSN: 0959-4965. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Section cross-reference(s): 2 Protein kinase B (PKB, or Akt), a downstream effector of phosphatidylinositol 3-kinase (PI-3-K), can play a crit. role in regulating neuronal survival. Among known targets of PKB, glycogen synthase kinase-3 (GSK-3) is inhibited by PKB-mediated phosphorylation. Recent studies implicate GSK-3 as a physiol. relevant principal regulatory target of the PI-3-K/PKB survival pathway. SB-216763 and SB-415286, selective small mol. inhibitors of GSK-3, protected cultured rat cerebellar granule neurons and hippocampal neurons against excitotoxicity mediated by NMDA and non-NMDA receptor agonists. Treatment with SB-216763 and SB-415286 was optimal when initiated 6-7 days before excitotoxin exposure. As GSK-3 can modulate transcriptional events, these results may provide insight into the identification of new neuroprotective targets. .